Full-Time

Director – Medical Science Liaison

KS, AR, LA, OK

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$220k - $260kAnnually

+ Commission + Bonus

Senior

Remote in USA

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Required Skills
Marketing
Requirements
  • Doctoral degree in scientific or medical discipline
  • 8+ years’ experience as an MSL or in a similar role within the pharmaceutical or biotech industry
  • Strong understanding of clinical research methodologies and drug development processes.
  • Knowledge and experience within the oncology therapeutic area
  • Excellent verbal and written communication skills.
  • Proven ability to analyze and synthesize scientific information effectively.
  • Excellent presentation skills, with the ability to effectively communicate complex scientific data to diverse audiences.
  • Strong networking skills with proven ability to successfully build and maintain relationships with KOLs and healthcare professionals.
  • Self-directed and able to thrive in a fast-paced and dynamic environment.
  • Willingness to travel up to 60% of time.
Responsibilities
  • Develop and maintain strong relationships with KOLs, healthcare professionals, and academic institutions to advance scientific and medical knowledge.
  • Communicate clinical and scientific data to KOLs and healthcare professionals through presentations, educational programs, and scientific discussions.
  • Support the synthesis and communicate scientific insights from KOLs to relevant internal teams.
  • Provide scientific support for medical congresses, advisory boards and other relevant scientific engagements to enhance the visibility of RevMed within the scientific and medical communities.
  • Establish credibility as a scientific expert and resource for internal stakeholders, providing medical and scientific support for products and therapeutic areas.
  • Collaborate cross-functionally with medical affairs, clinical development, marketing and other teams to support the development and execution of medical strategies and tactics.
  • Stay current with scientific literature, emerging research, and competitive landscape.
  • Adhere to Revolution Medicines Core Values and policies.
  • Understand the regulatory requirements for customer engagement by field-based employees.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

42%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.

Help us improve and share your feedback! Did you find this helpful?